Amneal Enters US Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
By, Admin1 min read
Share
Amneal Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
